Cytotoxicity profile of novel sterically hindered platinum(II) complexes with (1R,2R)-N1,N2-dibutyl-1,2-diaminocyclohexane

Anticancer Platinum(IV) Prodrugs Containing Monoaminophosphonate Ester as a Targeting Group Inhibit Matrix Metalloproteinases and Reverse Multidrug Resistance

“…Platinum agents such as cisplatin (CDDP), carboplatin, and oxaliplatin (OXP) are first-line antitumor drugs for chemotherapy. Among them, cisplatin is one of the most widely used chemotherapeutic agent in clinical treatment of numerous types of cancer. − However, its clinical drawbacks including serious toxicity, nonspecificity, and the development of tumor resistance to chemotherapy have confined the application of cisplatin. − Recently, platinum­(II) complexes conjugated with aminobisphosphonate and diethyl [(methylsulfinyl)­methyl]­phosphonate (SMP) ligands have also been reported to achieve bone tissue specificity. − In addition, some research indicated that platinum­(II) complexes containing SMP and diethyl (aminomethyl)­phosphonate (AMP) as carrier groups can significantly inhibit the activity of matrix metalloproteinases in vitro (Figure ). , Moreover, several research groups disclosed that platinum­(II) complexes containing phosphonate or bisphosphonate as nonleaving groups have excellent solubility in both organic and aqueous solutions and could potentially provide anticancer agents with bone-targeting ability (Figure ).…”

Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth—An Investigation of the Activation Mechanism and Their Nanoformulation

“…However, despite the undeniable clinical results, many drawbacks have emerged during the years of their medical use [ 10 , 11 ]. First of all, these drugs show debilitating side effects (such as severe vomiting, ototoxicity, nephrotoxicity, loss of appetite, and intense weakness) that in some cases force interruption of the clinical treatment [ 12 , 13 , 14 , 15 , 16 , 17 , 18 ]. Moreover, despite their initial effectiveness, it is not uncommon for cancer cells to develop resistance [ 12 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ].…”

“…First of all, these drugs show debilitating side effects (such as severe vomiting, ototoxicity, nephrotoxicity, loss of appetite, and intense weakness) that in some cases force interruption of the clinical treatment [ 12 , 13 , 14 , 15 , 16 , 17 , 18 ]. Moreover, despite their initial effectiveness, it is not uncommon for cancer cells to develop resistance [ 12 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. In order to overcome these drawbacks, many approaches have been explored over the years.…”

A Non-Conventional Platinum Drug against a Non-Small Cell Lung Cancer Line

“…Additionally, this specific MOA (through phosphate clamps) has been shown to lead to a different spectrum of clinical activity, targeting cellular entities beyond DNA such as proteins, enzymes, proteasomes or proteoglycans [ 16 ]. Furthermore, given their particular chemical features, the binding of non-hydrolysable Pt-complexes to other biomolecules during the pharmacokinetic phase (e.g., glutathione, serum albumin or metallothioneins) is not expected to be so extensive, which is expected to lead to a decreased toxicity (deleterious side-effects) and a lower acquired resistance [ 22 , 23 , 24 ]. Biogenic polyamines—putrescine, spermidine and spermine—are ubiquitous in all eukaryotic cells, being essential for cell proliferation and differentiation.…”